|
Product and Company U.S.
|
Development Status
|
|
Adenohepatitis B virus vaccine
|
Phase I
|
|
Wyeth-Ayerst
|
|
|
Acellular pertussis vaccine
|
Phase I/II
|
|
Massachusetts Department of Public Health
|
|
|
Acellular pertussis component
|
Phase I
|
|
Michigan Department of Public Health
|
|
|
Diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed
|
Phase III (infant efficacy study)
|
|
Lederle-Praxis Biologicals
|
|
|
Diphtheria and tetanus toxoids and acellular pertussis vaccine, adsorbed
|
Phase III
|
|
North American Vaccine
|
|
|
Diphtheria and tetanus toxoids and accellular pertussis vaccine, adsorbed and inactivated polio vaccine
|
Phase III
|
|
North American Vaccine
|
|
|
TetrammuneTM Diphtheria and tetanus toxoids and pertussis vaccine, adsorbed, and Haemophilus influenzae type b vaccine
|
PLA submitted (recommended for approval by FDA advisory committee, ages 2 months up to 7th birthday)
|
|
Lederle-Praxis Biologicals
|
|
|
Diptheria and tetanus toxoids and acellular pertussis vaccine, adsorbed, and Haemophilus influenzae type b conjugate vaccine
|
Phase II (for booster dose at 15–18 months of age or when both vaccines recommended to be given simultaneously)
|
|
Lederle-Praxis Biologicals
|
|
|
PropediaTM Diphtheria and tetanus toxoids and pertussis vaccine, adsorbed and Haemophilus influenzae type b vaccine (diphtheria toxoid conjugate)
|
PLA submitted (for 15–60 months of age as final booster dose in Hib series or as n single dose primary immunization at 15–60 months of age)
|
|
Connaught Laboratories, Inc.
|
|
|
Act HIBTM + DTP; Diptheria and tetanus toxoids Act HIB and pertussis vaccine, adsorbed, reconstituting Haemophilus influenzae type b conjugate vaccine (tetanus protein conjugate)
|
Submitted as part of PLA for alone (for 2–60 months of age)
|
|
Connaught Laboratories, Inc./Pasteur Mérieux Sérums et Vaccins
|
|
|
Act HIBTM + DTaP; Diptheria and tetanus toxoids and acellular pertussis vaccine, adsorbed, reconstituting Haemophilus influenzae type b conjugate vaccine (tetanus protein conjugate)
|
Phase II for 15–60 months of age
|
|
Connaught Laboratories, Inc./Pasteur Mérieux Sérums et Vaccins
|
